Skip to main content

Advertisement

SpringerLink
Log in

New Hormonal Contraceptives and New Roles for Established Hormonal Contraceptives

  • Published:
Current Pediatrics Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review presents features of the newest hormonal contraceptive options, as well as the most recent updates to the function of established contraceptive options.

Recent Findings

New contraception has been developed over the last several years, the features of which have provided new functionality for users. Some established forms of contraception have demonstrated increased functionality for users.

Summary

The new contraceptives improve access, effectiveness, privacy, and side effect profile. The vaginal system provides a user-operated/non-procedural year-long method. The transdermal system releases a lower hormone dose improving some adverse effects of estrogen, but demonstrates some loss of prior benefits, including effectiveness. The combined oral contraceptive premiers estetrol which is anticipated to decrease the risks associated with estrogen. The new progestin-only pill suppresses ovulation, allowing for improved flexibility in dosing. Mirena and Liletta IUDs, Nexplanon, and NuvaRing demonstrate extended length effectiveness, with the IUDs also proving effective in emergency contraception.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

Not applicable.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Youth Risk Behavior Survey Data Summary & Trends Report. Centers for Disease Control and Prevention: Atlanta GA. 2011-2021. Available from: www.cdc.gov/yrbs

  2. Hamilton EB, Martin AJ, Osterman JKM. Births: provisional data for 2022, vital statistics rapid release no. 28 centers for disease control and prevention: Atlanta GA. 2022. https://doi.org/10.15620/cdc:11602.

  3. Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. N Engl J Med. 2016;374:843–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kortsmit K, Nguyen AT, Mandel MG, Clark E, Hollier LM, Rodenhizer J, Whiteman MK. Abortion surveillance--United States. Morbidity and mortality weekly report surveillance summaries centers for disease control and prevention: Atlanta GA. 2020. Available from: https://stacks.cdc.gov/view/cdc/113007

  5. ACOG Committee Opinion No. 710: Counseling adolescents about contraception. Obst Gynecol. 2017:130. https://doi.org/10.1097/AOG.0000000000002228.

  6. Clare C, Squire M-B, Alvarez K, Meisler J, Fraser C. Barriers to adolescent contraception use and adherence. Int J Adolesc Med Health. 2018; https://doi.org/10.1515/ijamh-2016-0098.

  7. Ti A, Soin K, Rahman T, Dam A, Yeh PT. Contraceptive values and preferences of adolescents and young adults: a systematic review. Contraception. 2022;111:22–31.

    Article  PubMed  Google Scholar 

  8. Gemzell-Danielsson K, Sitruk-Ware R, Creinin MD, et al. Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation. Contraception. 2019;99:323–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Archer DF, Merkatz RB, Bahamondes L, et al. Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials. Lancet Glob Health. 2019;7:e1054–64.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Annovera (segesterone acetate and ethinyl estradiol vaginal system). Package Insert. US FDA approved product information. Boca Raton, FL: TherapeuticsMD, Inc; 2018.

    Google Scholar 

  11. Liu JH, Plagianos M, Archer DF, Simon JA, Kaunitz AM, Graham S, Bernick B, Mirkin S. Segesterone acetate serum levels with a regression model of continuous use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system. Contraception. 2021;104:229–34.

    Article  CAS  PubMed  Google Scholar 

  12. Golden NH. Bones and birth control in adolescent girls. J Pediatr Adolesc Gynecol. 2020;33:249–54.

    Article  PubMed  Google Scholar 

  13. Massai R, Mäkäräinen L, Kuukankorpi A, Klipping C, Duijkers I, Dieben T. The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women. Hum Reprod. 2005;20:2764–8.

    Article  CAS  PubMed  Google Scholar 

  14. Pierson RA, Archer DF, Moreau M, Shangold GA, Fisher AC, Creasy GW. Ortho Evra™/Evra™ versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril. 2003;80:34–42.

    Article  PubMed  Google Scholar 

  15. Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, Whiteman MK. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:1–66.

    PubMed  Google Scholar 

  16. Ortho Evra (norelgestromin/ethinyl estradiol) transdermal system. Package Insert. US FDA approved product information. Titusville, NJ: Janssen Ortho, Inc; 2017.

    Google Scholar 

  17. TWIRLA (levonorgestrel and ethinyl estradiol) transdermal system. Package Insert. US FDA approved product information. Grand Rapids, MI: Corium International Inc; 2022.

    Google Scholar 

  18. Nelson AL. The new low-dose transdermal contraceptive system (Twirla ® ): results from preclinical and Phase III trials. Ther Deliv. 2021;12:501–14.

    Article  CAS  PubMed  Google Scholar 

  19. Nelson AL, Kaunitz AM, Kroll R, Simon JA, Poindexter AN, Castaño PM, Ackerman RT, Flood L, Chiodo JA, Garner EI. Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results. Contraception. 2021;103:137–43.

    Article  CAS  PubMed  Google Scholar 

  20. Tepper NK, Dragoman MV, Gaffield ME, Curtis KM. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. Contraception. 2017;95:130–9.

    Article  CAS  PubMed  Google Scholar 

  21. Pfeifer S, Butts S, Dumesic D, et al. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril. 2017;107:43–51.

    Article  CAS  Google Scholar 

  22. Creinin MD, Westhoff CL, Bouchard C, Chen MJ, Jensen JT, Kaunitz AM, Achilles SL, Foidart J-M, Archer DF. Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results. Contraception. 2021;104:222–8.

    Article  CAS  PubMed  Google Scholar 

  23. Fruzzetti F, Fidecicchi T, Montt Guevara MM, Simoncini T. Estetrol: a new choice for contraception. J Clin Med. 2021;10:5625.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Khialani D, Rosendaal F, Vlieg AVH. Hormonal contraceptives and the risk of venous thrombosis. Semin Thromb Hemost. 2020;46:865–71.

    Article  PubMed  Google Scholar 

  25. Regidor P-A, Mueller A, Mayr M. Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen. Womens Health. 2023;19:174550572211473.

    Google Scholar 

  26. Nextstellis (drospirenone and estetrol tablets). Package Insert. US FDA approved product information. Greenville, NC: Mayne Pharma LLC; 2021.

    Google Scholar 

  27. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74:945–973.e33.

    Article  PubMed  Google Scholar 

  28. Slynd (drospirenone) tablets. Package Insert. US FDA approved product information. Florham Park, NJ: Exeltis USA, Inc; 2019.

    Google Scholar 

  29. Hoopes AJ, Simmons KB, Godfrey EM, Sucato GS. 2016 updates to US medical eligibility criteria for contraceptive use and selected practice recommendations for contraceptive use: highlights for adolescent patients. J Pediatr Adolesc Gynecol. 2017;30:149–55.

    Article  PubMed  Google Scholar 

  30. Glasier A, Sober S, Gasloli R, Goyal A, Laurora I. A review of the effectiveness of a progestogen-only pill containing norgestrel 75 μg/day. Contraception. 2022;105:1–6. A review that rounds up historical data for first OTC hormonal contraceptive that queries the widely held assumption of POP effectiveness.

    Article  CAS  PubMed  Google Scholar 

  31. Glasier A, Edelman A, Creinin MD, Brache V, Westhoff CL, Han L, Chen MJ, Hemon A. The effect of deliberate non-adherence to a norgestrel progestin-only pill: a randomized, crossover study. Contraception. 2023;117:1–6.

    Article  CAS  PubMed  Google Scholar 

  32. Creinin MD, Schreiber CA, Turok DK, Cwiak C, Chen BA, Olariu AI. Levonorgestrel 52 mg intrauterine system efficacy and safety through 8 years of use. Am J Obstet Gynecol. 2022;227:871.e1–7. A study expanding the definition of long-acting reversible contraception.

    Article  CAS  PubMed  Google Scholar 

  33. MIRENA (levonorgestrel-releasing intrauterine device). Package Insert. US FDA approved product information. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2000.

    Google Scholar 

  34. Turok DK, Gero A, Simmons RG, Kaiser JE, Stoddard GJ, Sexsmith CD, Gawron LM, Sanders JN. Levonorgestrel vs. copper intrauterine devices for emergency contraception. N Engl J Med. 2021:384, 335–44. A study establishing a new emergency contraceptive option.

  35. Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, Hubacher D. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod. 2016;31:2491–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Dragoman M, Petrie K, Torgal A, Thomas T, Cremers S, Westhoff CL. Contraceptive vaginal ring effectiveness is maintained during six weeks use: a prospective study of normal BMI and obese women. Contraception. 2013;87:432–6.

    Article  CAS  PubMed  Google Scholar 

  37. Mulders TMT, Dieben TOM. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril. 2001;75:865–70.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Adolescent Medicine, Department of Pediatrics, Stanford University School of Medicine, 750 Welch Rd, Ste 210, Palo Alto, CA, 94304, USA

    Brandii Criss

Authors
  1. Brandii Criss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brandii Criss.

Ethics declarations

Ethical Approval

Not applicable.

Competing Interests

The author declares no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Criss, B. New Hormonal Contraceptives and New Roles for Established Hormonal Contraceptives. Curr Pediatr Rep 11, 142–147 (2023). https://doi.org/10.1007/s40124-023-00299-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40124-023-00299-y

Keywords

Search

Navigation